SCHEMBL4078176

SCHEMBL4078176

N#Cc1cc(N)c2ccccc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.55
CA2 P00918 3/20 0.55
ALDH1A1 P00352 5/20 0.45
TSHR P16473 2/20 0.45
HSD17B10 Q99714 2/20 0.45
CYP3A4 P08684 1/20 0.45
HPGD P15428 1/20 0.45
KEAP1 Q14145 1/20 0.45
HPRT1 P00492 1/20 0.42
XDH P47989 1/20 0.42
SLC22A12 Q96S37 1/20 0.42
KDM4E B2RXH2 4/20 0.42
GAA P10253 2/20 0.42
ENPP3 O14638 1/20 0.41
ADORA2A P29274 1/20 0.40
CYP1B1 Q16678 2/20 0.38
CYP1A1 P04798 1/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5748557 0.85 CA1 (0.43) CA1CA2ALDH1A1TSHRHSD17B10
SCHEMBL689378 0.80 CYP1B1 (0.48) CA1CA2ALDH1A1TSHRHSD17B10
SCHEMBL9100044 0.80 ALDH1A1 (0.45) CA1CA2ALDH1A1TSHRHSD17B10
SCHEMBL4083551 0.78 CA1 (0.53) CA1CA2ALDH1A1TSHRHSD17B10
SCHEMBL819485 0.78 CA1 (0.56) CA1CA2ALDH1A1TSHRHSD17B10
SCHEMBL29482237 0.78 CA1 (0.56) CA1CA2ALDH1A1TSHRHSD17B10
SCHEMBL7304752 0.78 CA1 (0.61) CA1CA2ALDH1A1TSHRHSD17B10
SCHEMBL23087600 0.76 CA1 (0.59) CA1CA2ALDH1A1TSHRHSD17B10
SCHEMBL2641520 0.76 CA1 (0.55) CA1CA2ALDH1A1TSHRHSD17B10
SCHEMBL2186565 0.76 CA1 (0.55) CA1CA2ALDH1A1TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482339-B2 2-Naphthylimino-1,3-thiazine derivative SHIONOGI AND CO., LTD. (JP) 2009-01-27 US disclosed
US-20080262041-A1 Beta-Lactams for Treatment of Cns Disorders GLAXO GROUP LIMITED (GB) 2008-10-23 US disclosed
EP-1689737-B1 BETA-LACTAMS FOR THE TREATMENT OF CNS DISORDERS GLAXO GROUP LTD (GB) 2008-07-16 EP disclosed
US-20060281738-A1 2-Naphthylimino-1,3-thiazine derivative SHIONOGI AND CO., LTD. (JP) 2006-12-14 US disclosed
EP-1689737-A1 BETA-LACTAMS FOR THE TREATMENT OF CNS DISORDERS GLAXO GROUP LIMITED (GB) 2006-08-16 EP disclosed
EP-1659117-A1 2-NAPHTHYLIMINO-1,3-THIAZINE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2006-05-24 EP disclosed
WO-2005049600-A1 BETA-LACTAMS FOR TREATMENT OF CNS DISORDERS GLAXO GROUP LIMITED (GB) 2005-06-02 WO disclosed
US-4008326-A INCREASING PRODUCTION OF PROSTAGLANDINS THE UPJOHN COMPANY (US) 1977-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262041-A1 Beta-Lactams for Treatment of Cns Disorders SLC7A1, TPH1, CHRNA10 CA1 1918/4885CA2 2390/4885ALDH1A1 3393/4885
US-20060281738-A1 2-Naphthylimino-1,3-thiazine derivative NPM1, OXTR, CYP2S1 CA1 2192/4885CA2 300/4885ALDH1A1 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.